MedTrace Logo

AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia

NCT01431664 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2014-12-02

No results posted yet for this study

Summary

RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283 in treating young patients with relapsed or refractory acute leukemia.

Conditions

Interventions

DRUG

multikinase inhibitor AT9283

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Sponsors & Collaborators

Principal Investigators

  • Josef Vormoor · Sir James Spence Institute of Child Health at Royal Victoria Infirmary

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01431664 on ClinicalTrials.gov